Relmada Therapeutics (RLMD) - EPS (earnings per share)

EPS in 2026 (TTM): -£1.06

According to Relmada Therapeutics's latest financial reports the company's current EPS (TTM) is -£1.05. In 2025 the company made an earnings per share (EPS) of -£1.09 an increase over its 2024 EPS that were of -£1.99.

EPS history for Relmada Therapeutics from 2012 to 2026

Annual EPS

Year	EPS	Change
2026 (TTM)	-£1.06	-2.99%
2025	-£1.09	-45.28%
2024	-£1.99	-19.21%
2023	-£2.46	-38.11%
2022	-£3.98	-25.98%
2021	-£5.38	87.93%
2020	-£2.86	39.05%
2019	-£2.06	-4.2%
2018	-£2.15	37.5%
2017	-£1.56	100%
2016	-£0.78	-87.56%
2015	-£6.28
2013	-£0.02373	273.48%
2012	-£0.006353

EPS for similar companies or competitors

Company	EPS	EPS differencediff.	Country
Cytokinetics CYTK	-£5.14	388.57%	🇺🇸 USA
Taro Pharmaceutical TARO	£0.92	-187.14%	🇮🇱 Israel

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

EPS for Relmada Therapeutics (RLMD)

EPS in 2026 (TTM): -£1.06